CEO Update - 12 February 2024

Deep Biotech launch

It was great to see the hugely positive response we’ve had to the launch of our new report "Deep Biotech: Disruptive innovation for global sustainability"

I believe we're on the cusp of a biorevolution powered by Deep Biotech, and I want our Association at the forefront of shaping the future of Deep Biotech and championing its disruptive potential.

I hope this new resource for companies and policymakers does three things. First, explains the revolutionary power of Deep Biotech: unlocking its transformative applications and improving sustainability across various sectors, from energy and materials to food and the environment. Second, inspires and promotes through case studies: showcases cutting-edge companies pioneering Deep Biotech solutions, from sustainable biofuels to lab-grown meat, including Moa Technology, Solena Materials, Phycobloom, Quest Meat and Epoch Biodesign. Third, sets out key challenges and opportunities like addressing the regulatory, economic, and public acceptance hurdles Deep Biotech faces and outlines defining priorities and directions of its development to overcome them. 

It’s a call to action, inviting policymakers, investors, and the public to join us in harnessing the immense power of Deep Biotech. Together, we can build a more sustainable, healthier future for generations to come.

To celebrate the report’s publication, we held a launch event last week, kindly hosted by Osborne Clarke.

A panel of experts examined the opportunities and challenges for Deep Biotech from the perspective of business, government and the investor community.

It was wonderful to see so many mission-driven people, working across diverse industries, being brought together by the transformative power of Deep Biotech.

1707385557344.jpg

 

Major science and tech package to spark UK innovation and growth

It was pleasing to see the Secretary of State for Science, Innovation and Technology Michelle Donelan MP unveil a raft of new announcements to drive innovation in science to mark the department’s first anniversary.

£100 million has been awarded to six new ‘Engineering Biology Mission Hubs’ and 22 ‘Mission Award’ projects across the country, that will look to build on Engineering Biology’s enormous potential to address global challenges, drive economic growth, and increase national resilience. We look forward to engaging UK SMEs with the hubs and missions to grow the UK’s sustainable competitive advantage in this cutting-edge field.

The timely nature of these announcements reinforces that our commitment to Deep Biotech puts us firmly in the right place at the right time. Watch this space as we continue to support the burgeoning Deep Biotech community.

National Apprenticeship Week

During National Apprenticeships Week BIA member companies attended an Advanced Therapies Apprenticeship Community (ATAC) event at National Horizon Centre in Darlington as part of their annual roadshow. Gillian Keegan, Secretary of State for Education, attended this year's event hosted by Cell and Gene Therapy Catapult and Teesside University and was treated to a tour of the Advanced Therapies Skills and Training Network facilities, a practical demonstration in the training laboratories by apprentices from NHS Blood Transplant, CGT Catapult, Pharmaron and CPI and took part in an interactive workshop discussing opportunities and challenges of apprenticeships.

“Apprenticeships open doors to a range of exciting careers in our booming biosciences and healthcare sectors, so it’s great to see a dynamic organisation like CGT Catapult investing in future talent this National Apprenticeship Week. The northeast of England has a great tradition of industry and innovation, and apprenticeships are bringing that can-do spirit of hard graft into the 21st century, enabling people to pursue careers at the cutting edge of science and technology without necessarily needing to take on student debt.”  Education Secretary Gillian Keegan

With over 70% of occupations now covered by an apprenticeship route, there are plenty of opportunities across sectors, including science, digital and leadership roles, to bring in new talent to an organisation as well as upskill colleagues within the business. An apprentice can be anyone over the age of 16 with funding available for formal training and independent assessment against an approved standard from the apprenticeship levy. Gillian was delighted to present Andy Campbell from Pharmaron and a recent graduate of the Data Analyst apprenticeship (Distinction) with his graduation certificate from the ATAC – a moment he will definitely remember!

naw pics.PNG

 

naw pics 2.PNG

 

Notable developments

BIA member Autolus and BioNTech announced a strategic CAR-T Cell Therapy Collaboration last week. The alliance leverages manufacturing and commercial infrastructure as well as technology to advance both companies’ autologous CAR-T programs towards market and coincides with a new $600 million funding round for Autolus

It was also good to see Redx Pharma's latest deal with Jazz Pharmaceuticals, since as Lisa Anson, the chief executive of Redx Pharma, said “partnerships remain a key pillar of our corporate strategy”. Jazz will acquire Redx’s early-stage oncology programme developing inhibitors to target commonly occurring gene mutations to treat colorectal, pancreatic and lung cancer patients.

Indro Mukerjee stands down

Indro Mukerjee announced that he will conclude his role as CEO of Innovate UK at the end of September this year. Indro has been a strong champion of UK innovation and a trusted ally for us at the BIA, we look forward to eight more months of productive partnership and will continue to work closely with the entire Innovate UK team.

Ottoline Leyser, Chief Executive of UK Research and Innovation is also not seeking a second term of office and will step down at the end of June 2025.

Supply Chains Strategy

The Department of Business and Trade (DBT) have this month launched its new Critical Imports and Supply Chains Strategy. The Strategy sets out how government is working with business and international partners to build resilient supply chains, demonstrating that the UK is a safe and reliable place to do business. As part of the Strategy, the Supply Resilience Directorate has contributed a case study on the health supply chain, including the work of the National Supply Disruption Response (NSDR) team and long-term supply resilience projects we are undertaking in our sector. This case study can be found on page 27 of the Strategy, while a mention of our Industry Placement Scheme can be found on page 18. Read the press release.

Understanding the business requirements of the NHS Research SDE Network

NHS Research Secure Data Environment (SDE) Network is undertaking a survey to understand the business requirements of SDEs from health data users. They are interested in how access to a longitudinal patient-level dataset that captures the entire patient journey could help support industry, academia, and medical research charities' goals. Take part in this survey to share your views.

Sad news about Sir David Cooksey

I was saddened to hear of the death of Sir David Cooksey, aged 83. His vital contributions to the UK life sciences ecosystem we have today are too numerous to list here but the Francis Crick Institute – which he Chaired between 2009 and 2017 – has a must-read tribute to him. He was a British venture capital pioneer, and in later life instrumental in setting up the Crick and NIHR. The latter was the product of the Biosciences Innovation & Growth Taskforce, formed by the Government and BIA in 2003 and chaired by Sir David. He was kind enough to share with me exactly how he got things done over a memorable lunch a few years ago and I hope our work as an Association continues much of what he worked on in an honourable tradition. He will be missed and not forgotten.

Steve Bates Headshot.png

 

 

Steve Bates OBE
CEO, BioIndustry Association

More news and updates 

Aleta Biotherapeutics and Cancer Research UK announce first patient dosed in ALETA-001 Phase 1/2 clinical trial

The Phase 1/2 clinical trial will evaluate safety, dose, PK/PD, and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001. ALETA-001 entering the clinic is a critical milestone toward treatment availability to improve CAR T-cell patient response when a complete response is not achieved or maintained.

UKHSA announced as first PACE collaboration to help tackle deadly antimicrobial resistance

Strategic partnership to support AMR innovators

CEO Update - 20 February 2024

I'm looking forward to the BIA Committee Summit this week. It will be great to see 200 members in Westminster at one of the most lively and insightful events we do each year. I know it's the volunteer expert army that gives the BIA its unique impact with government and it's always great to understand the committee's priorities and the ideas at the intersection between committees that arise from the event.

Beyond health: why BIA is championing the biorevolution 

The BIA has named this frontier of science Deep Biotech. Our brand-new report, "Deep Biotech: Disruptive innovation for global sustainability" highlights how deep biotech is key to creating a sustainable UK bioeconomy and making the UK a science superpower that benefits all. 

PrecisionLife and Metrodora Institute partner to accelerate diagnosis of Long COVID

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases; targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year

Optibrium enables collaborative design in its StarDrop platform

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking.

Recent decision from the EPO smooths the way to obtaining patents in Europe

The BIA’s Intellectual Property Advisory Committee (IPAC) helps BIA understand and shape the environment for IP ownership to ensure strong protection for BIA member companies. Our EU policy subcommittee has taken a look at what a recent European decision means for the right to claim priority to an earlier filed patent application. This blog sets out some of the details of the case, and the practical implications for BIA members.​​​​​​​

BugBiome secures investment for pioneering research in sustainable pest protection

BugBiome raises £310,000 in pre-seed investment from Cambridge Angels and Discovery Park Ventures. Investment enables a £330,000 Engineering Biology Grant from Innovate UK for cutting-edge agri-tech research leveraging the microbiome and engineering biology approaches.

CEO Update - 12 February 2024

It was great to see the hugely positive response we’ve had to the launch of our new report "Deep Biotech: Disruptive innovation for global sustainability". I believe we're on the cusp of a biorevolution powered by Deep Biotech, and I want our Association at the forefront of shaping the future of Deep Biotech and championing its disruptive potential.

Study reveals POLB 001 could be a $10 billion game changer for cancer patients

Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS). Former Amryt Pharma team's arrival supports increasing focus upon Rare and Orphan Diseases

Enter the dragon: Exploring China’s life sciences market

Next week, Chinese people across the world will be celebrating Chinese New Year. This is the “year of the dragon”, a symbol of strength for the Chinese people. It also represents prosperity, a value Chinese strive for across aspects of life, society and business.

Demand for Golden Triangle lab space surges with highest annual volume since 2015

Demand for life sciences space in the ‘Golden Triangle’ surged in 2023, with the 925,000 sq ft of space representing the highest annual volume since 2015, according to the latest figures from Cushman & Wakefield.

More within